news
EU secures 80 million doses of Moderna COVID-19 vaccine
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
List view / Grid view
mRNA-1273
news
EMA initiates rolling review of Moderna’s COVID-19 vaccine
The rolling review will shorten the approval timeframe by evaluating data on the safety, efficacy and quality of the mRNA-1273 vaccine as it becomes available.
news
Moderna’s COVID-19 vaccine is 94.5 percent effective, according to interim analysis
The analysis reveals that mRNA-1273 was generally well tolerated and prevented COVID-19 with an efficacy of 94.5 percent in a Phase III study.
news
Takeda to supply Japan with Moderna’s COVID-19 vaccine
Takeda will import and distribute 50 million doses of the mRNA-1273 vaccine candidate under an agreement with Moderna and Government of Japan.
news
COVID-19 vaccine candidate well-tolerated in older adults
The experimental COVID-19 vaccine, mRNA-1273, was well-tolerated and elicited a strong immune response in older adults during a Phase I trial.
news
Moderna to supply US with initial 100 million doses of COVID-19 vaccine
Moderna will supply the US with at least 100 million doses of mRNA-1273, its COVID-19 vaccine candidate currently in Phase III clinical trials.
news
Moderna initiates Phase III trial of COVID-19 vaccine candidate
The first patients have been dosed in Moderna's Phase III clinical trial of its mRNA vaccine candidate to protect against COVID-19.
news
Experimental COVID-19 vaccine mRNA-1273 is safe and elicits response
Interim analysis of the Phase I trial data from 45 patients indicates mRNA-1273 can drive the production of antibodies targeting the SARS-CoV-2 spike protein.
news
Moderna and Catalent to collaborate on COVID-19 vaccine manufacture
Catalent's biologics facility will conduct large-scale, commercial fill-finish manufacturing of Moderna’s mRNA-based COVID-19 vaccine candidate.
news
FDA grants Fast Track Designation to Moderna’s COVID-19 vaccine
The US FDA has given Fast Track Designation to Moderna's mRNA vaccine candidate, mRNA-1273, designed to protect against COVID-19.
news
NIAID strategic plan for COVID-19 focuses on developing assays, therapeutics and vaccines
The US National Institute of Allergy and Infectious Diseases (NIAID) has revealed its research priorities relating to COVID-19, including supporting the development and testing of potential therapeutics and vaccines.
news
BARDA to give Moderna up to $483 million for COVID-19 vaccine development
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
article
Potential COVID-19 therapeutics currently in development
As the world rushes to identify the best coronavirus treatments and vaccines, John Cahill rounds up the latest developments in potential COVID-19 therapies.
news
First patient dosed in Phase I clinical trial for coronavirus vaccine
A Phase I clinical trial to investigate mRNA-1273, a vaccine to prevent the spread of the coronavirus COVID-19, has begun in the US.
news
COVID-19 update: therapeutic and regulatory developments
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
